BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: BMS-986484
Biological: Nivolumab

First Posted Date: 2024-08-09

Last Posted Date: 2024-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 134

Registration Number: NCT06544655

Locations: 🇨🇦
Local Institution - 0017, Toronto, Ontario, Canada
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Local Institution - 0003, Tucson, Arizona, United States

and more 8 locations

A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

Not yet recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: Deucravacitinib

First Posted Date: 2024-07-22

Last Posted Date: 2024-12-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 150

Registration Number: NCT06512337

Locations: 🇨🇳
Local Institution - 0001, Guangzhou, Guangdong, China
🇨🇳
Hangzhou Tigermed Consulting Co., Ltd., HangZhou, China

Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France

Recruiting

Conditions: Esophageal Adenocarcinoma (EAC)
Gastro-esophageal Junction Adenocarcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
Gastric Adenocarcinoma

Interventions: Drug: nivolumab + chemotherapy

First Posted Date: 2024-07-17

Last Posted Date: 2024-12-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 500

Registration Number: NCT06504615

Locations: 🇫🇷
KAPPA SANTE Institution, Paris, France
🇫🇷
Kappa Santé, Paris, France

Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer

Active, not recruiting

Conditions: Esophageal Cancer
Gastroesophageal Junction Cancer

Interventions: Drug: Nivolumab

First Posted Date: 2024-07-12

Last Posted Date: 2024-12-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 115

Registration Number: NCT06499298

Locations: 🇨🇳
Local Institution - 0001, Shanghai, China

A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants

Phase 1

Not yet recruiting

Conditions: Healthy Volunteers

Interventions: Drug: Repotrectinib
Drug: Voriconazole
Drug: Quinidine

First Posted Date: 2024-07-10

Last Posted Date: 2024-07-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT06493409

Locations: 🇺🇸
Fortrea - Daytona Beach, Daytona Beach, Florida, United States

A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Nivolumab + ipilimumab

First Posted Date: 2024-07-05

Last Posted Date: 2024-07-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 400

Registration Number: NCT06487156

Locations: 🇮🇹
Istituto Nazionale Tumori - IRCCS Fondazione G.Pascale, Napoli, Italy

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

Phase 1

Recruiting

Conditions: Healthy Volunteers
Anemia, Sickle Cell

Interventions: Drug: BMS-986470
Drug: Placebo

First Posted Date: 2024-07-01

Last Posted Date: 2024-07-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 184

Registration Number: NCT06481306

Locations: 🇺🇸
ICON, Lenexa, Kansas, United States

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of Single Doses of BMS-986435 (MYK-224) in Healthy Chinese Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BMS-986435

First Posted Date: 2024-06-26

Last Posted Date: 2024-11-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT06476821

Locations: 🇨🇳
Local Institution - 0001, Xuhui District, Shanghai, China

A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

Phase 4

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Deucravacitinib

First Posted Date: 2024-06-26

Last Posted Date: 2024-12-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT06476834

Locations: 🇺🇸
Local Institution - 0001, Las Vegas, Nevada, United States

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

Phase 1

Recruiting

Conditions: High-grade Serous Ovarian Carcinoma (HGSOC)
Uterine Serous Carcinoma (USC)
Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: BMS-986463

First Posted Date: 2024-06-26

Last Posted Date: 2024-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 240

Registration Number: NCT06476808

Locations: 🇨🇦
BC Cancer Vancouver, Vancouver, British Columbia, Canada
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States

and more 3 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy